Rekombinanter LAG3 (Relatlimab Biosimilar) Antikörper

Produktnummer ABIN7795123

Dieser Anti-LAG3 (Relatlimab Biosimilar) Antikörper ist ein Maus Monoklonal Antikörper zur Detektion von LAG3 (Relatlimab Biosimilar) in FACS und in vivo. Geeignet für Human.

Kurzübersicht für Rekombinanter LAG3 (Relatlimab Biosimilar) Antikörper (ABIN7795123)

Target: LAG3 (Relatlimab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser LAG3 (Relatlimab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-LAG3 (Relatlimab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody

Produktmerkmale: What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer. Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human LAG-3

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu LAG3 (Relatlimab Biosimilar)

Target: LAG3 (Relatlimab Biosimilar)

Andere Bezeichnung: Relatlimab Biosimilar

Substanzklasse: Biosimilar